LeafCann receives cannabis Manufacture Licence



LeafCann Group is one of the latest companies to receive a medicinal cannabis Manufacture Licence from the Office of Drug Control (ODC).

A Manufacture Licence allows LeafCann to process and manufacture raw cannabis material into medicinal cannabis products. The disused R&D pharmaceuticals site, on the outskirts of Adelaide in South Australia, now needs to be constructed and gain Good Manufacturing Practice (GMP) certification.

This follows the companies drastic move to cancel three applications last year following their purchase of the South Australia site, as the ODC was adamant they could not change site within a working application.

LeafCann’s CEO Elisabetta Faenza said, “After several years of Company development, I am delighted that LeafCann can now begin in earnest to execute our business plan towards delivering medicinal cannabis products to the many patients whose conditions are not treated effectively by existing pharmaceuticals, and whose quality of life could be substantially improved.

“The LeafCann team’s vision is to deliver a world class outcome for the medical market by leading the sector in the development of person-centred precision medicines under GMP (Good Manufacturing Practice) production. We look forward to continued engagement with regulators and licenced industry partners to provide effective, validated medicines to those that need it most.”

The company is still waiting on a Cannabis Cultivation Licence and a Cannabis Research Licence.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”